Skip to main content

Peer Review reports

From: Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

Original Submission
2 Jan 2023 Submitted Original manuscript
9 Jan 2023 Author responded Author comments - Peng Chen
13 Feb 2023 Reviewed Reviewer Report - Geoffrey Weiss
1 Mar 2023 Reviewed Reviewer Report - Masahiro Morise
22 Mar 2023 Reviewed Reviewer Report
2 Apr 2023 Author responded Author comments - Peng Chen
Resubmission - Version 2
9 Jan 2023 Submitted Manuscript version 2
8 Apr 2023 Author responded Author comments - Peng Chen
Resubmission - Version 3
8 Apr 2023 Submitted Manuscript version 3
9 Apr 2023 Author responded Author comments - Peng Chen
Resubmission - Version 4
9 Apr 2023 Submitted Manuscript version 4
17 Apr 2023 Reviewed Reviewer Report - Masahiro Morise
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
13 May 2023 Editorially accepted
19 May 2023 Article published 10.1186/s12885-023-10959-3

You can find further information about peer review here.

Back to article page